Cartesian Therapeutics, Inc. (RNAC) Earnings History
Net Loss12 years of earnings data (2014–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Cartesian Therapeutics, Inc. (RNAC) Earnings Overview
As of June 22, 2026, Cartesian Therapeutics, Inc. (RNAC) reported trailing twelve-month net income of -$152M, reflecting -52.6% year-over-year growth. The company earned $-5.65 per diluted share over the past four quarters, with a net profit margin of -4658.6%.
Looking at the long-term picture, RNAC's historical earnings data spans multiple years. The company achieved its highest annual net income of $35M in fiscal 2022.
Cartesian Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), IMVT (-$506M net income), ARQT (-$2M net income, -4.3% margin), RNAC has room to improve margins relative to the peer group. Compare RNAC vs KYMR →
RNAC Earnings vs Peers
Earnings metrics vs comparable public companies
RNAC Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$130M | -68.3% | -$87M | $-5.02 | -4658.6% | -3099.9% |
| 2024 | -$77M | +64.8% | -$44M | $-3.29 | -199.0% | -112.8% |
| 2023 | -$220M | -721.0% | -$86M | $-49.76 | -844.9% | -332.3% |
| 2022 | $35M | +237.7% | $15M | $3.00 | 31.9% | 13.1% |
| 2021 | -$26M | +62.7% | -$5M | $-6.60 | -30.2% | -5.4% |
| 2020 | -$69M | -24.4% | -$57M | $-20.42 | -415.0% | -342.4% |
| 2019 | -$55M | +15.3% | -$52M | $-36.46 | -829.0% | -785.6% |
| 2018 | -$65M | -0.0% | -$65M | $-87.55 | -7235.4% | -7200.7% |
| 2017 | -$65M | -80.4% | -$64M | $-95.94 | -31556.0% | -30813.5% |
| 2016 | -$36M | -43.8% | -$35M | $-103.52 | -448.0% | -428.9% |
| 2015 | -$25M | -95.5% | -$25M | $-75.79 | -418.8% | -421.0% |
| 2014 | -$13M | - | -$15M | $-38.17 | -423.7% | -506.5% |
Download Data
Export RNAC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RNAC — Frequently Asked Questions
Quick answers to the most common questions about buying RNAC stock.
What is RNAC earnings per share (EPS)?
RNAC trailing twelve-month (TTM) diluted EPS is $-5.65, reflecting -52.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2014 to 2025 is available in the table on this page.
What is Cartesian Therapeutics, Inc.'s net income?
Cartesian Therapeutics, Inc. (RNAC) trailing twelve-month net income is $-152M as of 2025. Earnings declined -52.6% year-over-year.
Is RNAC profitable?
RNAC is not currently profitable on a TTM basis, reporting a net loss of $-152M. Net margin is -4658.6%. Investors should monitor for a return to profitability.
What is RNAC's earnings growth rate?
RNAC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2014 to 2025.
What are RNAC's profit margins?
Cartesian Therapeutics, Inc. net profit margin is -4658.6%, operating margin is -3099.9%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is RNAC growing earnings?
RNAC earnings are declining — EPS fell -52.6% year-over-year. TTM net income dropped to $-152M. This contrasts with the 5-year CAGR of N/A.
What was RNAC's best earnings year?
Cartesian Therapeutics, Inc.'s highest annual net income on record is $35M, achieved in fiscal year 2022. Earnings history on this page spans 2014 to 2025 and includes all annual and quarterly figures.
What were RNAC's earnings last quarter?
RNAC's most recent reported quarter was Q1 2026. Net income was $-39M with diluted EPS of $-1.46. For a full breakdown of all quarters, see the quarterly earnings table on this page.